Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250880 | 0.87 | HMGCR (0.64) | TAAR1HMGCRHTR2APTGS2CYP3A4 | |
| SCHEMBL24119648 | 0.85 | HTR2A (0.61) | TAAR1HMGCRHTR2AALOX5PTGS2 | |
| SCHEMBL13868273 | 0.84 | TAAR1 (0.58) | TAAR1HMGCRHTR2APTGS2CYP3A4 | |
| SCHEMBL19751445 | 0.81 | HTR2A (0.54) | TAAR1HMGCRHTR2AALOX5PTGS2 | |
| SCHEMBL23222349 | 0.80 | HMGCR (0.72) | TAAR1HMGCRHTR2AALOX5CYP3A4 | |
| SCHEMBL31456015 | 0.79 | ALDH1A1 (0.49) | TAAR1HTR2AALOX5PTGS2PPARA | |
| SCHEMBL13964126 | 0.79 | TAAR1 (0.60) | TAAR1HMGCRHTR2ACYP3A4 | |
| SCHEMBL25143280 | 0.79 | HMGCR (0.50) | TAAR1HMGCRPTGS2CYP3A4 | |
| SCHEMBL19751507 | 0.78 | HTR2A (0.51) | TAAR1HMGCRHTR2AALOX5PTGS2 | |
| SCHEMBL25434544 | 0.77 | HTR2A (0.46) | TAAR1HMGCRHTR2AALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226096-A1 | BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | MERCK PATENT GMBH (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20130023522-A1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226096-A1 | BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | TAAR1 1717/4885HMGCR 4671/4885HTR2A 211/4885 |
| US-20130023522-A1 | BENZAMIDES | FSHR, GNRHR, LHCGR | TAAR1 1991/4885HMGCR 4372/4885HTR2A 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.